TSC 발병 및 진행 중지 2B: Sirolimus TSC 간질 예방 연구 (TSC-STEPS)
This trial is a Phase II randomized, double-blind, placebo controlled multi-site study to evaluate the safety and efficacy of early sirolimus to prevent or delay seizure onset in TSC infants.
This study is supported by research funding from the Office of Orphan Products Division (OOPD) of the US Food and Drug Administration (FDA).
연구 개요
상태
상태
정황
정황
개입 / 치료
개입 / 치료
상세 설명
Tuberous Sclerosis Complex (TSC) is caused by genetic mutation in TSC1 or TSC2, resulting in dysregulation of the mechanistic target of rapamycin (mTOR) signaling pathway. Age at time of seizure onset in TSC infants has been linked to long-term neurodevelopmental outcome in this high-risk population. Sirolimus is an mTOR inhibitor used to treat many of the symptoms of TSC, including epilepsy. This will be the first study to truly evaluate a targeted, disease-modifying drug therapy for preventing or delaying seizure onset in TSC using a rational, mechanism-based therapeutic approach.
연구 유형
연구 유형
등록 (추정된)
등록
단계
단계
- 2 단계
연락처 및 위치
연구 장소
-
-
Alabama
-
Birmingham, Alabama, 미국, 35294
- University of Alabama at Birmingham
-
-
California
-
Los Angeles, California, 미국, 90095
- University of California at Los Angeles
-
Palo Alto, California, 미국, 94304
- Stanford University
-
-
Massachusetts
-
Boston, Massachusetts, 미국, 02115
- Boston Children's Hospital
-
-
North Carolina
-
Chapel Hill, North Carolina, 미국, 27510
- University of North Carolina at Chapel Hill
-
-
Ohio
-
Cincinnati, Ohio, 미국, 45229
- Cincinnati Children's Hospital Medical Center
-
-
Texas
-
Houston, Texas, 미국, 77030
- University of Texas HSC at Houston
-
-
Washington
-
Seattle, Washington, 미국, 98105
- Seattle Children's Hospital
-
-
참여기준
자격 기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- 0-6 months of age at the time of enrollment (subject must be <7 months of chronological age at time of randomization and treatment initiation). Corrected age must be at least 39 weeks (calculated by subtracting the number of weeks born before 40 weeks gestation from the chronological age).
- Has a confirmed diagnosis of TSC based on established clinical or genetic criteria
Exclusion Criteria:
- Prior history of seizures (clinical or electrographic) at the time of enrollment or identified on baseline EEG.
- Has been treated in the past or is currently being treated at the time of enrollment with conventional anticonvulsant medications (AEDs), systemic (oral) mTOR inhibitors (such as rapamycin, sirolimus, or everolimus), ketogenic-related special diet, or another anti-seizure therapeutic agent, device, or procedure.
- Has taken any other investigational drug as part of another research study, within 30 days prior to the baseline screening visit.
- Has a significant illness or active infection at the time of the baseline screening visit
- Has a history of significant prematurity, defined as gestational age <30 weeks at the time of delivery, or other significant medical complications at birth or during the neonatal period that other than TSC would convey additional risk of seizures or neurodevelopmental delay (i.e. HIE, severe neonatal infection, major surgery, prolonged ventilatory or other life-saving supportive care or procedures).
- Abnormal laboratory values at baseline (i.e., renal function, liver function, or bone marrow production) that are in the opinion of the investigator clinically significant and may jeopardize the safety of the study subject.
- Prior, planned or anticipated neurosurgery within 3 months of the baseline visit
- Has a TSC-associated condition for which mTOR treatment is clinically indicated (i.e. SEGA or AML).
- Subjects who are, in the opinion of the investigator, unable to comply with the requirements of the study.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 방지
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 삼루타
팔의 수
무기와 개입
참가자 그룹 / 팔참가자 그룹 / 팔 |
개입 / 치료개입 / 치료 |
|---|---|
|
위약 비교기: Placebo
Placebo |
Matching placebo |
|
실험적: Sirolimus
Sirolimus |
The investigational drug product to be used in this study is sirolimus, provided in oral suspension. |
연구는 무엇을 측정합니까?
주요 결과 측정
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Efficacy -- time to seizure onset
기간: 12 months of age
|
Time to seizure onset, comparing sirolimus with placebo |
12 months of age
|
|
Safety -- adverse events
기간: 12 months of age
|
Percentage of subjects reporting severe (CTCAE v5.0 grade >= 3) adverse event (AE) or serious adverse event (SAE), comparing sirolimus with placebo. |
12 months of age
|
2차 결과 측정
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Neurodevelopmental Outcomes
기간: 12 and 24 months of age
|
Neurodevelopmental outcomes at the end of treatment, comparing sirolimus with placebo. |
12 and 24 months of age
|
|
Quality of Life Outcomes
기간: 12 and 24 months of age
|
Patient and caregiver quality of life, comparing sirolimus with placebo. |
12 and 24 months of age
|
|
EEG Biomarkers
기간: 12 and 24 months of age
|
EEG measures of neuronal connectivity, comparing sirolimus with placebo. |
12 and 24 months of age
|
|
MRI Biomarkers
기간: 12 and 24 months of age
|
MRI measures of neuronal connectivity, comparing sirolimus with placebo. |
12 and 24 months of age
|
|
Sirolimus Precision Dosing
기간: 12 months of age
|
Validate the feasibility and effectiveness of sirolimus precision dosing in infants with TSC |
12 months of age
|
공동 작업자 및 조사자
수사관
수사관
- 수석 연구원: Darcy A Krueger, MD, PhD, Children's Hospital Medical Center, Cincinnati
- 수석 연구원: Martina Bebin, MD, MPA, University of Alabama at Birmingham
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
연구 시작
기본 완료 (추정된)
기본 완료
연구 완료 (추정된)
연구 완료
연구 등록 날짜
최초 제출
최초 제출
QC 기준을 충족하는 최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
처음 게시됨
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
마지막 업데이트 게시됨
QC 기준을 충족하는 마지막 업데이트 제출
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
기타 연구 ID 번호
- 2021-0438
- 1R01FD007275 (미국 FDA 승인/계약)
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .